Loading organizations...
§ Private Profile · Seoul, Seoul-t'ukpyolsi, South Korea
Clinical-stage biopharmaceutical company developing AI-driven therapeutic cancer vaccines for oncology, focused on solid tumors.
Aston Sci is a Seoul, South Korea-based clinical-stage biopharmaceutical company that develops plasmid DNA-based and mRNA therapeutic cancer vaccines for oncology and immunology applications. The organization utilizes its proprietary AI-driven Th-Vac platform to identify specific epitopes and stimulate patient immune systems against solid tumors. The firm maintains a drug pipeline of 11 therapeutic vaccines, with lead candidates such as AST-301 advancing into Phase 2 clinical trials for breast and gastric cancers. Aston Sci has raised over 48 billion KRW in total funding, including a 27 billion KRW Series C round backed by investors such as Timefolio Asset Management, KB Investment, and Shinhan Venture Investment. The enterprise also collaborates with strategic partners like EpiThany Inc. and utilizes the CDD Vault platform to advance its clinical research. Hun Woo Shin originally founded the biopharmaceutical company in October 2018.
Aston Sci has raised $22.7M across 1 funding round.
Aston Sci has raised $22.7M in total across 1 funding round.
Aston Sci has raised $22.7M across 1 funding round. Most recently, it raised $22.7M Series C in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 3, 2022 | $22.7M Series C | — | Mirae Asset Venture Investment, Timefolio Asset Management | Announced |
Aston Sci has raised $22.7M in total across 1 funding round.
Aston Sci's investors include Mirae Asset Venture Investment, Timefolio Asset Management.